Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
For reference, in 2024, about 2.2 million Medicare patients received semaglutide products, equal to just 4% of the 53 million Medicare Part D enrollees.The prevalence of obesity alone is estimated to be 34% in the Medicare population, corresponding to an additional 16 million Medicare beneficiaries that would qualify for semaglutide products
Mehmetoglu I, Yerlikaya FH, Kurban S, Erdem SS, Tonbul Z
Affordability and Other Barriers Despite their popularity, access to GLP-1 medications remains uneven
It is important to make research more available for this percentage of ME/CFS cases, since they are the most severely affected by the disease and these severe cases are rarely studied (53)
US$ 26.48
US$ 25.32
US$ 24.52
US$ 28.09
US$ 29.21
US$ 26.57
US$ 20.66
US$ 29.36
US$ 24.04
US$ 26.27
